bexarotene has been researched along with Cell Transformation, Neoplastic in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (12.50) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Atigadda, VR; Boerma, LJ; Brouillette, WJ; Desphande, A; Grubbs, CJ; Lobo-Ruppert, S; Muccio, DD; Smith, CD; Xia, G | 1 |
| Alpdogan, SO; Cha, J; Correia, E; Krishnasamy, S; Nikbakht, N; O'Donnell, M; Porcu, P; Sahu, J; Shi, W; Zaya, R | 1 |
| Bratescu, L; Christov, K; Green, A; Shilkaitis, A; Yamada, T | 1 |
| Broussard, KC; Patrawala, SA; Wang, L; Zic, JA | 1 |
| Baker, R; Bissonnette, RP; Brown, PH; Dannenberg, AJ; Howe, LR; Newman, RA; Salmon, AP; Subbaramaiah, K; Yang, P; Zhou, XK | 1 |
| Choi, CI; Janakiram, NB; Mohammed, A; Qian, L; Rao, CV; Steele, VE | 1 |
| Apisarnthanarax, N; Duvic, M; Ha, CS | 1 |
| Kremer, R; Solomon, C; White, JH | 1 |
8 other study(ies) available for bexarotene and Cell Transformation, Neoplastic
| Article | Year |
|---|---|
Methyl substitution of a rexinoid agonist improves potency and reveals site of lipid toxicity.
Topics: Animals; Anticarcinogenic Agents; Apoptosis; Bexarotene; Binding Sites; Cell Line; Cell Proliferation; Cell Transformation, Neoplastic; Crystallography, X-Ray; Fatty Acids, Unsaturated; Female; Humans; Hyperlipidemias; Mammary Neoplasms, Experimental; Models, Molecular; Molecular Structure; Naphthalenes; Rats; Retinoid X Receptor alpha; Stereoisomerism; Structure-Activity Relationship; Tetrahydronaphthalenes; Transcriptional Activation | 2014 |
Disease characteristics, prognosis, and response to therapy in patients with large-cell transformed mycosis fungoides: A single-center retrospective study.
Topics: Bexarotene; Brentuximab Vedotin; Cell Transformation, Neoplastic; Humans; Mycosis Fungoides; Prognosis; Retrospective Studies; Skin Neoplasms | 2022 |
Bexarotene induces cellular senescence in MMTV-Neu mouse model of mammary carcinogenesis.
Topics: Animals; Anticarcinogenic Agents; Bexarotene; Cell Transformation, Neoplastic; Cellular Senescence; Female; Genes, erbB-2; Mammary Neoplasms, Experimental; Mammary Tumor Virus, Mouse; Mice; Mice, Transgenic; Tetrahydronaphthalenes; Up-Regulation | 2013 |
Tumor stage mycosis fungoides: a single-center study on clinicopathologic features, treatments, and patient outcome.
Topics: Age Factors; Aged; Anticarcinogenic Agents; Antineoplastic Agents; Bexarotene; Cell Transformation, Neoplastic; Disease Progression; Female; Furocoumarins; Humans; Male; Middle Aged; Mycosis Fungoides; Neoplasm Staging; Prognosis; Radiotherapy; Retrospective Studies; Skin; Skin Neoplasms; Tertiary Care Centers; Tetrahydronaphthalenes; Ultraviolet Therapy | 2016 |
Combination chemoprevention of HER2/neu-induced breast cancer using a cyclooxygenase-2 inhibitor and a retinoid X receptor-selective retinoid.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Carcinoma; Celecoxib; Cell Transformation, Neoplastic; Chemoprevention; Cyclooxygenase 2 Inhibitors; Drug Evaluation, Preclinical; Eicosanoids; Female; Genes, erbB-2; Mammary Neoplasms, Experimental; Mammary Tumor Virus, Mouse; Mice; Mice, Transgenic; Pyrazoles; Retinoid X Receptors; Retinoids; Substrate Specificity; Sulfonamides; Tetrahydronaphthalenes | 2008 |
Chemopreventive effects of RXR-selective rexinoid bexarotene on intestinal neoplasia of Apc(Min/+) mice.
Topics: Adenomatous Polyposis Coli; Adenomatous Polyposis Coli Protein; Animals; Anticarcinogenic Agents; Bexarotene; Cell Proliferation; Cell Transformation, Neoplastic; Cyclin D1; Cyclooxygenase 2; Cytokines; Drug Screening Assays, Antitumor; Female; Intestinal Mucosa; Intestinal Neoplasms; Male; Maximum Tolerated Dose; Mice; Mice, Inbred C57BL; Oleic Acid; Retinoid X Receptor alpha; Tetrahydronaphthalenes; Triglycerides | 2012 |
Mycosis fungoides with follicular mucinosis displaying aggressive tumor-stage transformation : successful treatment using radiation therapy plus oral bexarotene combination therapy.
Topics: Administration, Oral; Adult; Anticarcinogenic Agents; Bexarotene; Cell Transformation, Neoplastic; Chemotherapy, Adjuvant; Female; Humans; Mucinosis, Follicular; Mycosis Fungoides; Skin Neoplasms; Tetrahydronaphthalenes | 2003 |
Mitogen-activated protein kinase inhibits 1,25-dihydroxyvitamin D3-dependent signal transduction by phosphorylating human retinoid X receptor alpha.
Topics: Animals; Anticarcinogenic Agents; Bexarotene; Calcitriol; Calcium-Calmodulin-Dependent Protein Kinases; Cell Line, Transformed; Cell Transformation, Neoplastic; COS Cells; Drug Resistance, Neoplasm; Genes, ras; Humans; Keratinocytes; Mutagenesis, Site-Directed; Phenotype; Phosphorylation; Receptors, Calcitriol; Receptors, Retinoic Acid; Retinoid X Receptors; Serine; Signal Transduction; Tetrahydronaphthalenes; Transcription Factors; Transfection; Tumor Cells, Cultured | 1999 |